Literature DB >> 26707728

Epigenetic alternations and cancer chemotherapy response.

Jin-Feng Lv1,2, Lei Hu1,2, Wei Zhuo1,2, Cong-Min Zhang1,2, Hong-Hao Zhou1,2, Lan Fan3,4.   

Abstract

Epigenetics, referring to alterations in gene expression without a change in nucleotide sequence in eukaryotes, mainly includes DNA methylation, miRNA and histone modification. In recent years, accumulating evidences have shown that epigenetic aberrations not only play important roles in the initiation and development of human cancers but also affect cancer chemotherapy response by altering the expression of key genes involved in the absorption, distribution, metabolism and excretion of drugs or those correlated with progression or severity of cancers. These epigenetic alterations, along with advanced detecting techniques, have great potential to be used as predictive and prognostic biomarkers for personalized therapy, especially in the field of cancer treatment. Here we provide an overview of recent findings on epigenetic alterations involved in cancer chemotherapy response, with the aim of promoting rational use of chemotherapy drugs in the clinic.

Entities:  

Keywords:  Biomarker; Cancer chemotherapy response; DNA methylation; Epigenetics; Histone modification; Personalized therapy; miRNA

Mesh:

Substances:

Year:  2015        PMID: 26707728     DOI: 10.1007/s00280-015-2951-0

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  Stochastic tuning of gene expression enables cellular adaptation in the absence of pre-existing regulatory circuitry.

Authors:  Peter L Freddolino; Jamie Yang; Amir Momen-Roknabadi; Saeed Tavazoie
Journal:  Elife       Date:  2018-04-05       Impact factor: 8.140

2.  Downregulation of PRMT5 by AMI-1 enhances therapeutic efficacy of compound kushen injection in lung carcinoma in vitro and in vivo.

Authors:  Ruiying Yang; Shuhong Dong; Jinghui Zhang; Shihao Zhu; Guoliang Miao; Baolai Zhang
Journal:  Mol Cell Biochem       Date:  2022-10-10       Impact factor: 3.842

Review 3.  Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.

Authors:  Rogerio M Castilho; Cristiane H Squarize; Luciana O Almeida
Journal:  Int J Mol Sci       Date:  2017-07-12       Impact factor: 5.923

Review 4.  Pharmacogenetic testing in oncology: a Brazilian perspective.

Authors:  Guilherme Suarez-Kurtz
Journal:  Clinics (Sao Paulo)       Date:  2018-10-11       Impact factor: 2.365

5.  Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study.

Authors:  Song Yao; Qiang Hu; Sarah Kerns; Li Yan; Adedayo A Onitilo; Jamal Misleh; Kelley Young; Lianlian Lei; Javier Bautista; Mostafa Mohamed; Supriya G Mohile; Christine B Ambrosone; Song Liu; Michelle C Janelsins
Journal:  Clin Epigenetics       Date:  2019-03-12       Impact factor: 6.551

6.  The Relation of Haplotype ATP-binding Cassette B1 and Glutathione S-transferase P1 A313G Genes with Hematological Toxicity in Indonesian Breast Cancer Patients Receiving Chemotherapy.

Authors:  Siti Syarifah; Tri Widyawati; Dita Hasni; Mutiara Indah Sari; Rusdiana Rusdiana; Tasrif Hamdi
Journal:  Oman Med J       Date:  2022-03-22

7.  Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1).

Authors:  Yixue Gu; Zhijie Zhang; Jiang Yin; Jiahui Ye; Yin Song; Hao Liu; Yan Xiong; Minying Lu; Guopei Zheng; Zhimin He
Journal:  J Exp Clin Cancer Res       Date:  2017-08-31

8.  EDNRB isoform 3 confers Temozolomide resistance in A375 melanoma cells by modulating membrane potential, reactive oxygen species and mitochondrial Ca2.

Authors:  Yun Shan Chen; Fen Liu; Yi Hong Luo; Yue Fan; Fang Gui Xu; Pin Li; Bei Zhou; Xiu Yu Pan; Chi Chiu Wang; Long Cui
Journal:  Cancer Manag Res       Date:  2019-08-05       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.